Clinical Trials Logo

Urinary Obstruction clinical trials

View clinical trials related to Urinary Obstruction.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06181175 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

ProSeRePEA
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the efficacy of the supplement PEAPROSTIL 600 (FARMITALIA®) composed of Serenoa Repens combined with PEA in single or combined therapy with alpha-blocker in the reduction of voiding symptoms in benign prostatic hyperplasia (BPH) patients at low risk of progression to obstructing conditioning that need for surgical therapy. Any adverse events, intolerance, allergic reactions, complications related to the products used will be recorded throughout the study period.

NCT ID: NCT05640115 Recruiting - Cancer Clinical Trials

Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent

Start date: September 22, 2023
Phase: Early Phase 1
Study type: Interventional

This research study will compare two procedures commonly used to treat urinary obstruction due to cancer. Sometimes cancer blocks one or both ureters (narrow tubes in the body that carry urine from the kidneys to the bladder). When these ureters become blocked, the body can no longer properly drain urine. This blocking of the ureters is called urinary obstruction, which can lead to kidney problems, infection, and pain. Treatment options for urinary obstruction include ureteral stent placement and percutaneous nephrostomy tube placement. Both treatment options require a doctor to place soft tubes (like a catheter) inside the body to help the ureters properly drain urine. These two treatment options have different success rates, risks, and effects on quality of life. By doing this study, researchers hope to learn which treatment option is best for individuals who develop urinary obstruction because of cancer. Participation in this research will last about 3 months.

NCT ID: NCT04288427 Recruiting - Clinical trials for Benign Prostatic Hyperplasia

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.